- Home
- ZTEK vs DTIL Comparison
ZTEK vs DTIL Comparison
Compare ZTEK & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- DTIL
- Stock Information
- Founded
- ZTEK 2008
- DTIL 2006
- Country
- ZTEK Canada
- DTIL United States
- Employees
- ZTEK N/A
- DTIL N/A
- Industry
- ZTEK Major Chemicals
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- DTIL Health Care
- Exchange
- ZTEK Nasdaq
- DTIL Nasdaq
- Market Cap
- ZTEK 89.3M
- DTIL 81.4M
- IPO Year
- ZTEK N/A
- DTIL 2019
- Fundamental
- Price
- ZTEK $0.76
- DTIL $4.82
- Analyst Decision
- ZTEK
- DTIL Strong Buy
- Analyst Count
- ZTEK 0
- DTIL 2
- Target Price
- ZTEK N/A
- DTIL $47.00
- AVG Volume (30 Days)
- ZTEK 58.9K
- DTIL 252.6K
- Earning Date
- ZTEK 11-14-2025
- DTIL 11-03-2025
- Dividend Yield
- ZTEK N/A
- DTIL N/A
- EPS Growth
- ZTEK N/A
- DTIL N/A
- EPS
- ZTEK N/A
- DTIL N/A
- Revenue
- ZTEK $657,134.00
- DTIL $698,000.00
- Revenue This Year
- ZTEK N/A
- DTIL N/A
- Revenue Next Year
- ZTEK N/A
- DTIL $135.19
- P/E Ratio
- ZTEK N/A
- DTIL N/A
- Revenue Growth
- ZTEK 2225.73
- DTIL N/A
- 52 Week Low
- ZTEK $0.62
- DTIL $3.61
- 52 Week High
- ZTEK $1.84
- DTIL $8.82
- Technical
- Relative Strength Index (RSI)
- ZTEK 46.41
- DTIL 30.38
- Support Level
- ZTEK $0.75
- DTIL $4.68
- Resistance Level
- ZTEK $0.83
- DTIL $5.41
- Average True Range (ATR)
- ZTEK 0.06
- DTIL 0.57
- MACD
- ZTEK -0.01
- DTIL -0.27
- Stochastic Oscillator
- ZTEK 22.48
- DTIL 4.90
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.